{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:49Z","timestamp":1791219469738,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.biocel.2012.07.011","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T05:33:29Z","timestamp":1342762409000},"page":"1729-1738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Proteasome deubiquitinases as novel targets for cancer therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"P\u00e1draig","family":"D\u2019Arcy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.biocel.2012.07.011_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.biocel.2012.07.011_bib0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.biocel.2012.07.011_bib0020","first-page":"S44","article-title":"TGF-beta signaling in cancer \u2013 a double-edged sword","volume":"11","author":"Akhurst","year":"2001","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1515\/BC.2000.121","article-title":"Analysis of the deubiquitinating enzymes of the yeast saccharomyces cerevisiae","volume":"381","author":"Amerik","year":"2000","journal-title":"Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/MCB.00909-09","article-title":"The ubiquitin ligase Hul5 promotes proteasomal processivity","volume":"30","author":"Aviram","year":"2010","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0035","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/ijc.24004","article-title":"Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system","volume":"124","author":"Berndtsson","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.biocel.2012.07.011_bib0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.biocel.2012.07.011_bib0045","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1093\/emboj\/20.18.5187","article-title":"A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14","volume":"20","author":"Borodovsky","year":"2001","journal-title":"EMBO Journal"},{"key":"10.1016\/j.biocel.2012.07.011_bib0050","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1074\/jbc.272.14.9086","article-title":"Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance","volume":"272","author":"Bush","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0055","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nsmb1276","article-title":"YY1 functions with INO80 to activate transcription","volume":"14","author":"Cai","year":"2007","journal-title":"Nature Structural and Molecular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nature Clinical Practice Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0070","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.pharmtox.45.120403.100037","article-title":"Proteasome inhibition in multiple myeloma: therapeutic implication","volume":"45","author":"Chauhan","year":"2005","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0075","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0080","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0085","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/0008-5472.CAN-09-4428","article-title":"Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib","volume":"70","author":"Chen","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0090","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/cbf.1734","article-title":"Effect of ubiquitin carboxy-terminal hydrolase 37 on apoptotic in A549 cells","volume":"29","author":"Chen","year":"2011","journal-title":"Cell Biochemistry and Function"},{"key":"10.1016\/j.biocel.2012.07.011_bib0095","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","article-title":"Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132","volume":"66","author":"Crawford","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D\u2019Arcy","year":"2011","journal-title":"Nature Medicine"},{"key":"10.1016\/j.biocel.2012.07.011_bib0105","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1074\/jbc.M110.149633","article-title":"Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease","volume":"286","author":"Dammer","year":"2011","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biochi.2007.09.013","article-title":"Targeting ubiquitin specific proteases for drug discovery","volume":"90","author":"Daviet","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.biocel.2012.07.011_bib0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ncb845","article-title":"Proteasome subunit Rpn1 binds ubiquitin-like protein domains","volume":"4","author":"Elsasser","year":"2002","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1073\/pnas.0408592102","article-title":"Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis","volume":"102","author":"Erdal","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.biocel.2012.07.011_bib0125","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.molcel.2005.04.016","article-title":"The 1.9 A structure of a proteasome-11S activator complex and implications for proteasome-PAN\/PA700 interactions","volume":"18","author":"Forster","year":"2005","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0135","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2011.443","article-title":"Deubiquitinases in cancer: new functions and therapeutic options","volume":"31","author":"Fraile","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2012.07.011_bib0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.biocel.2012.07.011_bib0145","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","article-title":"Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells","volume":"24","author":"Fribley","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/1535-7163.MCT-06-0542","article-title":"The JAMM motif of human deubiquitinase Poh1 is essential for cell viability","volume":"6","author":"Gallery","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81603-7","article-title":"A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3","volume":"94","author":"Glickman","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1042\/BST0350012","article-title":"Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy","volume":"35","author":"Goldberg","year":"2007","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.biocel.2012.07.011_bib0165","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0170","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0175","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1074\/jbc.M307050200","article-title":"Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome","volume":"279","author":"Guterman","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0180","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1074\/jbc.M109.038331","article-title":"The anti-apoptotic protein BCL2L1\/Bcl-xL is neutralized by pro-apoptotic PMAIP1\/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression","volume":"285","author":"Hagenbuchner","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0185","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/sj.emboj.7601338","article-title":"A novel proteasome interacting protein recruits the deubiquitinating enzyme UCH37 to 26S proteasomes","volume":"25","author":"Hamazaki","year":"2006","journal-title":"EMBO Journal"},{"key":"10.1016\/j.biocel.2012.07.011_bib0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cell.2006.07.038","article-title":"Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation","volume":"127","author":"Hanna","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0200","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/S0021-9258(20)82050-X","article-title":"Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown","volume":"258","author":"Hershko","year":"1983","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0205","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0210","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0215","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0220","doi-asserted-by":"crossref","first-page":"28019","DOI":"10.1074\/jbc.274.39.28019","article-title":"Interaction of hHR23 with S5a, the ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome","volume":"274","author":"Hiyama","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1083\/jcb.150.1.119","article-title":"The regulatory complex of Drosophila melanogaster 26S proteasomes, subunit composition and localization of a deubiquitylating enzyme","volume":"150","author":"Holzl","year":"2000","journal-title":"Journal of Cell Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0230","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature06926","article-title":"Proteasome subunit Rpn13 is a novel ubiquitin receptor","volume":"453","author":"Husnjak","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1126\/science.275.5296.90","article-title":"Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK\/JNK and p38 signaling pathways","volume":"275","author":"Ichijo","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.biocel.2012.07.011_bib0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/embor.2008.93","article-title":"Atypical ubiquitin chains: new molecular signals, \u2018Protein Modifications: Beyond the Usual Suspects\u2019 review series","volume":"9","author":"Ikeda","year":"2008","journal-title":"EMBO Reports"},{"key":"10.1016\/j.biocel.2012.07.011_bib0245","doi-asserted-by":"crossref","first-page":"35485","DOI":"10.1074\/jbc.M109.052928","article-title":"The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26s proteasome","volume":"284","author":"Jacobson","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0255","doi-asserted-by":"crossref","first-page":"41207","DOI":"10.1074\/jbc.M509128200","article-title":"A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex","volume":"280","author":"Jin","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0260","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1091\/mbc.e07-10-1040","article-title":"Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome","volume":"19","author":"Koulich","year":"2008","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2404414","article-title":"Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells","volume":"21","author":"Kraus","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.biocel.2012.07.011_bib0270","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0275","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.biocel.2012.07.011_bib0280","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0285","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/385737a0","article-title":"Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome","volume":"385","author":"Lam","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0290","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.biocel.2012.07.011_bib0295","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature10774","article-title":"Complete subunit architecture of the proteasome regulatory particle","volume":"482","author":"Lander","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0300","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428190902866732","article-title":"Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia","volume":"50","author":"Laubach","year":"2009","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.biocel.2012.07.011_bib0305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0310","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R110.003871","article-title":"Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes","volume":"10","author":"Lee","year":"2011","journal-title":"Molecular Cell Proteomics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(02)00638-X","article-title":"Multiple associated proteins regulate proteasome structure and function","volume":"10","author":"Leggett","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-29-8","article-title":"Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types","volume":"29","author":"Ling","year":"2010","journal-title":"Journal of Experimental and Clinical Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0325","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells","volume":"278","author":"Ling","year":"2003","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0330","doi-asserted-by":"crossref","first-page":"e5544","DOI":"10.1371\/journal.pone.0005544","article-title":"Regulation of ErbB2 receptor status by the proteasomal DUB POH1","volume":"4","author":"Liu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.biocel.2012.07.011_bib0335","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","volume":"37","author":"Lu","year":"2009","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0340","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1128\/MCB.23.15.5320-5330.2003","article-title":"Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13","volume":"23","author":"Lundgren","year":"2003","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0345","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0350","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.freeradbiomed.2011.06.022","article-title":"Uncoupling proteins and the control of mitochondrial reactive oxygen species production","volume":"51","author":"Mailloux","year":"2011","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.biocel.2012.07.011_bib0355","doi-asserted-by":"crossref","first-page":"13854","DOI":"10.1073\/pnas.0913495107","article-title":"Regulation of NF-kappaB activity and inducible nitric oxide synthase by regulatory particle non-ATPase subunit 13 (Rpn13)","volume":"107","author":"Mazumdar","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.biocel.2012.07.011_bib0360","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1074\/jbc.M808507200","article-title":"Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativation","volume":"284","author":"Mines","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0365","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0370","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-11-0853","article-title":"Molecular pathways: targeting proteasomal protein degradation in cancer","volume":"18","author":"Molineaux","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0375","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/mol.62.2.351","article-title":"Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death","volume":"62","author":"Mullally","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0380","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm1049","article-title":"How the ubiquitin-proteasome system controls transcription","volume":"4","author":"Muratani","year":"2003","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0385","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1152\/physrev.00023.2010","article-title":"Large potentials of small heat shock proteins","volume":"91","author":"Mymrikov","year":"2011","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.biocel.2012.07.011_bib0390","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","article-title":"Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0395","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1535-7163.MCT-04-0260","article-title":"The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim","volume":"4","author":"Nikrad","year":"2005","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0400","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0405","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0410","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0415","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0420","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2007-12-130781","article-title":"The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies","volume":"112","author":"Paoluzzi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0425","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0430","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.molcel.2009.11.015","article-title":"Ubiquitinated proteins activate the proteasome by binding to Usp14\/Ubp6, which causes 20S gate opening","volume":"36","author":"Peth","year":"2009","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0435","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0440","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.onc.1210679","article-title":"A pivotal role for Mcl-1 in Bortezomib-induced apoptosis","volume":"27","author":"Podar","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2012.07.011_bib0445","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1124\/jpet.112.191536","article-title":"ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines","volume":"341","author":"Premkumar","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0450","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1038\/sj.emboj.7601450","article-title":"hRpn13\/ADRM1\/GP110 is a novel proteasome subunit that binds the deubiquitinating enzyme, UCH37","volume":"25","author":"Qiu","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.biocel.2012.07.011_bib0455","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molcel.2008.03.004","article-title":"Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases","volume":"30","author":"Rabl","year":"2008","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0460","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.biocel.2012.07.011_bib0465","first-page":"596","article-title":"Bortezomib: a novel therapy approved for multiple myeloma","volume":"1","author":"Richardson","year":"2003","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0470","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.biocel.2012.07.011_bib0475","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.biocel.2012.07.011_bib0480","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0485","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1091\/mbc.9.10.2917","article-title":"A mutation in a novel yeast proteasomal gene, RPN11\/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology","volume":"9","author":"Rinaldi","year":"1998","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0490","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/mc.20177","article-title":"Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines","volume":"45","author":"Rolen","year":"2006","journal-title":"Molecular Carcinogenesis"},{"key":"10.1016\/j.biocel.2012.07.011_bib0495","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells","volume":"23","author":"Ruckrich","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biocel.2012.07.011_bib0500","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.biocel.2012.07.011_bib0505","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.biocel.2012.07.011_bib0510","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0515","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature06924","article-title":"Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction","volume":"453","author":"Schreiner","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0520","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.biocel.2012.07.011_bib0525","first-page":"539","article-title":"Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases","volume":"15","author":"Shinji","year":"2006","journal-title":"Oncology Reports"},{"key":"10.1016\/j.biocel.2012.07.011_bib0530","doi-asserted-by":"crossref","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","article-title":"Noxa\/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells","volume":"286","author":"Smith","year":"2011","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0535","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.06.033","article-title":"Docking of the proteasomal ATPases\u2019 carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry","volume":"27","author":"Smith","year":"2007","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0540","doi-asserted-by":"crossref","first-page":"30470","DOI":"10.1074\/jbc.272.48.30470","article-title":"Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26S proteasome subunit","volume":"272","author":"Spataro","year":"1997","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0545","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jmb.2004.09.057","article-title":"Uch2\/Uch37 is the major deubiquitinating enzyme associated with the 26S proteasome in fission yeast","volume":"344","author":"Stone","year":"2004","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0550","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0555","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","article-title":"Inactivating PSMB5 mutations and P-glycoprotein (MDR1\/ABCB1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno) proteasome inhibitors in mononuclear blood cells from rheumatoid arthritis patients","volume":"341","author":"Verbrugge","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.biocel.2012.07.011_bib0560","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.1075898","article-title":"Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome","volume":"298","author":"Verma","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.biocel.2012.07.011_bib0565","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1100946","article-title":"Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain","volume":"306","author":"Verma","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.biocel.2012.07.011_bib0570","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0575","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin-proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0580","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.molcel.2008.02.014","article-title":"Histone ubiquitination: triggering gene activity","volume":"29","author":"Weake","year":"2008","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0585","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1038\/sj.onc.1208944","article-title":"The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling","volume":"24","author":"Wicks","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2012.07.011_bib0590","first-page":"7338","article-title":"The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells","volume":"63","author":"Williams","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0595","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/nsmb1332","article-title":"A YY1-INO80 complex regulates genomic stability through homologous recombination-based repair","volume":"14","author":"Wu","year":"2007","journal-title":"Nature Structural and Molecular Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0600","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.106.030015","article-title":"The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from Indian winter cherry","volume":"71","author":"Yang","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0605","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1349-7006.2004.tb03200.x","article-title":"Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK\/c-Jun\/AP-1 signaling","volume":"95","author":"Yang","year":"2004","journal-title":"Cancer Science"},{"key":"10.1016\/j.biocel.2012.07.011_bib0610","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nature01071","article-title":"A cryptic protease couples deubiquitinylation and degradation by the proteasome","volume":"419","author":"Yao","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biocel.2012.07.011_bib0615","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.molcel.2008.08.027","article-title":"Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex","volume":"31","author":"Yao","year":"2008","journal-title":"Molecular Cell"},{"key":"10.1016\/j.biocel.2012.07.011_bib0620","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ncb1460","article-title":"Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1","volume":"8","author":"Yao","year":"2006","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.biocel.2012.07.011_bib0625","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","article-title":"The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib","volume":"295","author":"Yu","year":"2004","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.biocel.2012.07.011_bib0630","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1476-4598-9-110","article-title":"Characterization of bortezomib-adapted I-45 mesothelioma cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.biocel.2012.07.011_bib0635","doi-asserted-by":"crossref","first-page":"25540","DOI":"10.1074\/jbc.M111.260505","article-title":"Ubiquitin chain trimming recycles the substrate binding sites of the 26S proteasome and promotes degradation of lysine 48-linked polyubiquitin conjugates","volume":"286","author":"Zhang","year":"2011","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0640","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.biocel.2012.07.011_bib0645","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1038\/sj.onc.1208683","article-title":"Bik\/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors","volume":"24","author":"Zhu","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.biocel.2012.07.011_bib0650","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2010-08-304022","article-title":"RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5","volume":"117","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biocel.2012.07.011_bib0655","doi-asserted-by":"crossref","first-page":"26008","DOI":"10.1074\/jbc.274.37.26008","article-title":"An archaebacterial ATPase, homologous to ATPases in the eukaryotic 26S proteasome, activates protein breakdown by 20 S proteasomes","volume":"274","author":"Zwickl","year":"1999","journal-title":"Journal of Biological Chemistry"}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272512002506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272512002506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:47:56Z","timestamp":1761202076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272512002506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":131,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1357272512002506"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2012.07.011","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome deubiquitinases as novel targets for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2012.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}